BioCardia, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
BioCardia, Inc. (BCDA) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $4.12 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-12
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $4.12M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $951.00K.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $2.50M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $5.29M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations |
|---|---|
| 2026-06-30 | $4.12M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $951.00K 10-Q · filed 2026-05-15 |
| 2025-12-31 | $2.50M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $5.29M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $980.00K 10-Q · filed 2026-08-12 |
| 2025-03-31 | $949.00K 10-Q · filed 2026-05-15 |
| 2024-12-31 | $2.37M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $4.93M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $1.42M 10-Q/A · filed 2025-10-29 |
| 2024-03-31 | $949.00K 10-Q · filed 2025-05-14 |
| 2023-12-31 | $1.10M 10-K · filed 2026-03-24 |
| 2023-09-30 | $1.83M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $4.30M 10-Q · filed 2024-08-13 |
| 2023-03-31 | $4.86M 10-Q · filed 2024-05-14 |
| 2022-12-31 | $7.36M 10-K · filed 2025-03-26 |
| 2022-09-30 | $6.67M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $8.61M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $9.93M 10-Q · filed 2023-05-10 |
| 2021-12-31 | $12.87M 10-K · filed 2024-03-27 |
| 2021-09-30 | $15.89M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $18.54M 10-Q · filed 2022-08-10 |
| 2021-03-31 | $21.50M 10-Q · filed 2022-05-11 |
| 2020-12-31 | $21.41M 10-K · filed 2023-03-29 |
| 2020-09-30 | $7.39M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $11.09M 10-Q · filed 2021-08-12 |
| 2020-03-31 | $2.59M 10-Q · filed 2021-05-13 |
| 2019-12-31 | $5.58M 10-K · filed 2022-03-29 |
| 2019-09-30 | $8.91M 10-Q · filed 2020-11-10 |
| 2019-06-30 | $517.00K 10-Q · filed 2020-08-13 |
| 2018-12-31 | $5.36M 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |